Home › Compare › BPSR vs ORCC

BPSR vs ORCC: Dividend Comparison 2026

BPSR yields 3333.33% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BPSR wins by $1244041712890.38M in total portfolio value
10 years
BPSR
BPSR
● Live price
3333.33%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1244041712890.40M
Annual income
$1,174,716,366,071,938,000.00
Full BPSR calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — BPSR vs ORCC

📍 BPSR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPSRORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPSR + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BPSR pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPSR
Annual income on $10K today (after 15% tax)
$283,333.33/yr
After 10yr DRIP, annual income (after tax)
$998,508,911,161,147,300.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, BPSR beats the other by $998,508,911,161,147,300.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPSR + ORCC for your $10,000?

BPSR: 50%ORCC: 50%
100% ORCC50/50100% BPSR
Portfolio after 10yr
$622020856445.21M
Annual income
$587,358,183,035,969,000.00/yr
Blended yield
94.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

BPSR
No analyst data
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPSR buys
0
ORCC buys
0
No recent congressional trades found for BPSR or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPSRORCC
Forward yield3333.33% ✓9.79%
Annual dividend / share$2.00 ✓$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0% ✓-50%
Portfolio after 10y$1244041712890.40M ✓$21.4K
Annual income after 10y$1,174,716,366,071,938,000.00 ✓$1.04
Total dividends collected$1239274250481.68M ✓$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: BPSR vs ORCC ($10,000, DRIP)

YearBPSR PortfolioBPSR Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$344,033$333,333.33$11,190$489.61+$332.8K → BPSR
2$11,085,665$10,717,549.33$12,229$256.01+$11.07M → BPSR
3$334,616,633$322,754,971.08$13,216$130.74+$334.60M → BPSR
4$9,462,934,690$9,104,894,892.71$14,207$66.02+$9462.92M → BPSR
5$250,766,259,005$240,640,918,887.41$15,234$33.17+$250766.24M → BPSR
6$6,228,082,462,189$5,959,762,565,053.11$16,317$16.62+$6228082.45M → BPSR
7$144,998,525,500,125$138,334,477,265,582.72$17,468$8.32+$144998525.48M → BPSR
8$3,165,074,899,913,431$3,009,926,477,628,297.00$18,695$4.16+$3165074899.89M → BPSR
9$64,790,043,755,570,470$61,403,413,612,663,110.00$20,006$2.08+$64790043755.55M → BPSR
10$1,244,041,712,890,398,500$1,174,716,366,071,938,000.00$21,407$1.04+$1244041712890.38M → BPSR

BPSR vs ORCC: Complete Analysis 2026

BPSR — Stock

Organicell Regenerative Medicine, Inc. processes, distributes, and supplies biologically processed cellular and tissue-based products in the United States. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. has an agreement with Regenerative Care Network to study potential therapeutic benefits of Zofin for patients with heart failure. Organicell Regenerative Medicine, Inc. was founded in 2011 and is headquartered in Miami, Florida.

Full BPSR Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this BPSR vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPSR vs SCHDBPSR vs JEPIBPSR vs OBPSR vs KOBPSR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.